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Abstract It has been established that leptin displays a number
of effects on peripheral tissues. We have investigated the effect of
the hormone on lipid synthesis, apolipoprotein biogenesis and
lipoprotein secretion in Caco-2 cells. Immunocytochemistry
revealed the presence of leptin receptors (Ob-Rb) on the
basolateral membrane. Incubation of cells with 200 nM leptin
resulted in a decreased export of triglycerides in the basolateral
medium without affecting monoglyceride, diglyceride and
cholesterol ester lipid classes. It also significantly reduced the
output of de novo-synthesized apolipoprotein (Apo)B-100 and
ApoB-48 as well as that of newly formed chylomicrons and of
low-density lipoproteins. It also enhanced that of ApoA-I, ApoA-
IV and ApoE. Our results support the hypothesis that leptin can
affect energy balance at the gut level by reducing lipid release
into the circulation. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
The lipid content of the diet has considerably increased over
the past century and has contributed to the epidemics of obe-
sity in Western countries, as most clearly illustrated in pop-
ulations that have experienced a sudden change in dietary
habits, such as Pima Indians, and the Australian Aborigines
[1,2]. Due to the high-caloric value of fat nutrients and the
relative e⁄ciency of intestinal handling, fat absorption and
post-prandial lipemia have become a major focus of obesity
research.
It is generally accepted that leptin, a peptide hormone dis-
covered in 1994 by Zhang et al. [3], controls appetite and
increases energy expenditure at the hypothalamic level. In
humans, its concentrations generally correlate positively with
obesity [4^6]. Its importance in human physiology has further
been exempli¢ed in patients with multiple endocrine defects
and immune dysfunction in whom a missense mutation of the
leptin gene caused its de¢ciency [7]. However, in the vast
majority of obese human subjects elevated leptin concentra-
tions are observed, indicating a leptin-resistant state rather
than leptin de¢ciency [8,9].
In recent years, it has clearly been established that leptin,
besides its central role at the hypothalamic level, displays a
number of e¡ects on a variety of cells and peripheral tissues.
For example, leptin inhibits basal insulin secretion and glu-
cose-stimulated insulin secretion in normal and ob/ob mice
[10]. Furthermore, leptin shows a diuretic action in hydrated
rodents, probably through speci¢c receptors localized in the
internal kidney medulla [11]. On the other hand, its acute
administration has been reported to decrease white adipose
tissue lipogenesis and increase fat mobilization [12]. Further-
more, although acute treatment of ob/ob mice with recombi-
nant leptin rapidly caused a stimulation of liver long-chain
fatty acid synthesis, chronic treatment diminished the de
novo fatty acid synthesis [13], thereby impacting on lipopro-
tein synthesis. Accordingly, other in vivo experiments using
ob/ob mice have shown impaired liver high-density lipopro-
tein (HDL)^apolipoprotein which can be reversed by low-dose
leptin treatment [14]. Similarly, disturbances occur in ob/ob
mouse hepatocytes HDL^lipoprotein binding, degradation
and secretion processing which can be corrected by leptin [15].
Closer to the present report, it is interesting to note that the
baseline leptin level could be predicted from body mass index
and circulating apolipoprotein A-I (ApoA-I) concentration in
obese children [16]. Surprisingly, the in£uence of leptin on the
elaboration of apolipoproteins and of HDL by the intestine,
an organ contributing 50% of total circulating lipids and lipo-
proteins, has not been investigated. Morton et al. [17] have
reported the presence of functional leptin receptors in the
mouse jejunum and in di¡erentiated Caco-2 cells. They have
also shown that intravenous leptin administration, 15 min
before a fat load, paradoxically reduced jejunal ApoA-IV
transcript levels. Aside from these data, and the recent report
of Doi et al. [18] who also reported that the simultaneous
intravenous administration of leptin and duodenal lipid load
attenuated the increase of cellular ApoA-IV content, little in-
formation is available, to our knowledge, on the role of leptin
in intestinal lipid synthesis, apolipoprotein biogenesis and
lipoprotein secretion.
In the present report we have investigated the e¡ect of
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human recombinant leptin (hrLeptin) on lipid handling in
fully di¡erentiated Caco-2 cells.
2. Materials and methods
2.1. Cell culture
Caco-2 cells obtained from the ATCC (Bethesda, MD, USA) were
grown at 37‡C with 5% CO2 in minimum essential medium (MEM;
Gibco-BRL, Grand Island, NY, USA) in 175 cm2 plastic £asks
(Corning, NY, USA) as described in detail previously [19,20]. The
medium contained 1% penicillin/streptomycin, 1% MEM non-essential
amino acids (Gibco-BRL) and was supplemented with 10% decom-
plemented fetal bovine serum (FBS; Flow McLean, VA, USA). Cul-
tures (passages 30^40) were split (1:3^1:6) upon reaching 70^90%
con£uency, using 0.05% trypsin^EDTA (0.5 mM; Gibco-BRL).
For individual experiments, cells were plated at a density of 1U106
cells/well on 24.5-mm polycarbonate Transwell ¢lter inserts with 0.4-
Wm pores (Costar, Cambridge, MA, USA), in MEM (as above) sup-
plemented with 5% FBS. The inserts were placed into six-well culture
plates, permitting separate access to the upper (apical) and lower
(basolateral) compartments of the monolayers. Cells were cultured
for 20 days, at which time Caco-2 cells were highly di¡erentiated
[21]. For a more e⁄cient induction of lipid, lipoprotein and apolipo-
protein synthesis, cells were incubated in presence of unlabeled oleic
acid, bound to albumin, in a serum-free medium, for 20 h prior to the
experiments. Transepithelial resistance, an index of con£uence and
tight junction integrity, was determined using a Millicel-ERS appara-
tus (Millipore, Bedford, MA, USA) [22].
2.2. E¡ect of leptin on the de novo lipid synthesis
Radiolabeled [14C]oleic acid (Amersham, Oakville, ON, Canada)
was added to unlabeled oleic acid and solubilized in fatty acid free-
bovine serum albumin [23,24]. The ¢nal oleic acid concentration was
1 Wmol/well with 0.45WCi of [14C]oleic acid attached to albumin. 200
nM hrLeptin in 5% FBS-supplemented MEM (RpD Systems Inc.,
Minneapolis, MN, USA), concentration at which maximal e¡ects
were observed by Morton et al. [17] in the same model, was then
added to the basolateral compartment. Cells were incubated for a
period of 8 h at 37‡C, in the presence of [14C]oleic acid-containing
medium added to the apical compartment. At the end of the incuba-
tion period, the basolateral medium was collected and the cells were
scraped in cell lysis bu¡er as described previously [20]. After the
addition of anti-proteases (phenylmethylsulfonyl £uoride, pepstatin,
leupeptin and trasylol), the lipids contained in the cell lysates and
medium were extracted by standard methods [23^25] in presence of
unlabeled carrier phospholipids, monoglycerides (MGs), diglycerides
(DGs), triglycerides (TGs) free fatty acids (FFAs) and cholesteryl
ester (CE).
The various lipid classes were separated by thin-layer chromatog-
raphy (TLC) using a ternary solvent system consisting of hexane/
ether/acetic acid (80:20:3, v/v) as previously described [26]. The area
corresponding to each lipid standard, run simultaneously, was scraped
o¡ the TLC plates, placed in a vial with Ready Safe0 counting £uid
(Beckman, Montreal, QC, Canada) and counted on a scintillation
counter (Beckman LS 5000 TD) to determine its radioactivity content.
Proteins were measured by the method of Lowry et al. [27] using
bovine serum albumin as standard. Results were reported as disinte-
gration per minute/mg protein.
2.3. E¡ect of leptin on the de novo apolipoprotein synthesis
As previously mentioned, cells were incubated in presence of non-
labeled oleic acid (1 WM) attached to albumin to stimulate apolipo-
protein synthesis. After 20 h, cells were carefully washed with methio-
nine-free MEM and incubated for 3 h in the presence of
[35S]methionine (150 WCi/well, 50 mCi/mmol; Amersham, Oakville,
ON, Canada). At the end of the labeling period, the medium of the
basolateral compartment was collected and cells scraped in a lysis
bu¡er. Aliquots of cell homogenates and basolateral medium were
precipitated with 5% trichloracetic acid (TCA). The precipitates
were washed (three times) with 5% TCA before counting the radio-
activity on a Beckman liquid scintillation spectrometer. Other centri-
fuged aliquots were reacted with excess monoclonal antibodies di-
rected against ApoA-I, Apo-IV, ApoB and ApoE for 18 h at 4‡C.
Following the addition of Pansorbin (Calbiochem, San Diego, CA,
USA), the mixture was incubated at 20‡C for 60 min and the immu-
noprecipitate extensively washed before being submitted to gradient
(4^15%) polyacrylamide electrophoresis as already described [28^30].
Gels were sectioned into 4-mm slices and counted after overnight
incubation at 20‡C with 1 ml of BTS-450 (Beckman) and 10 ml of
Ready Solve0 liquid scintillation £uid.
2.4. E¡ect of leptin on the de novo lipoprotein synthesis
For the determination of the newly synthesized and secreted lipo-
Fig. 1. Protein A^gold labeling of di¡erentiated Caco-2 cells for the speci¢c functional leptin receptor Ob-Rb. Con£uent cells were ¢xed in situ
with 1% glutaraldehyde, processed for embedding in Lowicryl at 320‡C and processed by the immunogold to reveal the Ob-Rb receptor. The
labeling by colloidal gold particles is present along the basolateral membrane (blm) of the Caco-2 cells, while the apical membrane lining the
microvilli (mv) is devoid of labeling.
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proteins, cells were incubated for a prolonged period of 20 h in pres-
ence of 200 nM hrLeptin and 1.0 Wmol/well of unlabeled oleic acid
containing 0.9 WCi of [14C]oleic acid so as to detect an appreciable
amount of lipoproteins secreted into the basolateral medium. At the
end of the incubation period, the basolateral medium was collected
and supplemented with protease inhibitors and a plasma carrier in the
ratio (2.0/0.6, v/v) [31]. Lipoproteins were then isolated by sequential
ultracentrifugation using a TL-100 Beckman ultracentrifuge as per
our described method [23]. Each lipoprotein fraction was exhaustively
dialyzed against 0.15 M NaCl, 0.001 M EDTA, pH 7.0, at 4‡C for 245
h before being counted.
2.5. Immunocytochemistry
The antibody against the leptin receptor (Ob-Rb) was purchased
from RpD Systems Inc. This rabbit polyclonal IgG [(Ob-R (H-300)]
is directed against the epitope corresponding to amino acids 541^840
mapping within a cytoplasmic domain of the human Ob-Rb [32].
Con£uent cells were ¢xed in situ with 1% glutaraldehyde and pro-
cessed for embedding in Lowicryl at 320‡C as described previously
[33]. Thin sections were mounted on Parlodion and carbon-coated
nickel grids and processed for immunocytochemistry using the immu-
nogold approach [33]. In short, the sections were incubated overnight
at 4‡C with the anti-Ob-Rb antibody diluted 1:20. The sections were
then rinsed with 0.01 M phosphate-bu¡ered saline and incubated with
the protein A^gold complex for 1 h at room temperature. The protein
A^gold complex was prepared with 10 nm gold particles according to
the previously reported protocols [33]. Control experiments were per-
formed to assess the speci¢city of the labeling. The sections were
incubated with a normal serum followed by protein A^gold or with
protein A^gold alone, omitting the ¢rst antibody. For the quantitative
evaluations, the plasma membrane pro¢les of 25 cells were recorded
and printed to a ¢nal magni¢cation of U50 000. The density of label-
ing present over the apical and basolateral membranes was evaluated
by measuring the length of the membranes and the number of par-
ticles being aligned on such membranes [33]. The results are expressed
as the number of gold particles per length (Wm).
2.6. Statistical analysis
Conventional methods were used for calculation of means and stan-
dard error. Statistical signi¢cance for di¡erences in variables between
control and hrLeptin-treated cells was assessed with the Student’s
t-test.
3. Results
In order to reveal the distribution of leptin receptors, sec-
tions of Caco-2 cells were exposed to the anti-Ob-Rb antibody
followed by the protein A^gold complex. The gold particles
were particularly present at the level of the basolateral mem-
brane (Fig. 1A), while only few particles localized over the
apical membrane (Fig. 1B). Furthermore, speci¢c labeling ap-
peared to be absent, with only few particles distributed in the
cytoplasm, mitochondria and nuclei. Quantitative evaluations
con¢rmed the presence of a speci¢c higher labeling at the
basolateral membrane (Table 1). The absence of labeling
with protein A^gold in the absence of the primary antibody
con¢rmed the speci¢city of our immunocytochemical method
(Table 1).
As shown in Table 2, incubation of fully di¡erentiated
Caco-2 cells with 200 nM hrLeptin on the basolateral side
for 8 h did not a¡ect cell content of any of the de novo-syn-
thesized lipid fractions. It resulted, however, in a decreased
export of TG (68 þ 15%, P6 0.01) in the basolateral medium,
compared to controls, without a¡ecting MG, DG and CE
lipid classes.
Fig. 2A,B illustrates the e¡ects of hrLeptin on the de novo
synthesis of apolipoproteins assessed after a 3-h incubation
with [35S]methionine as a tracer. Under these conditions,
hrLeptin signi¢cantly reduced the cell content of de novo-syn-
thesized ApoB-100 and ApoB-48 by 32% (P6 0.05) and 22%
(P6 0.01), respectively (Fig. 2A). Similarly, the presence of
the hormone diminished the output of ApoB-100 and
ApoB-48 by 33% (P6 0.01) and 40% (P6 0.05), respectively,
in the basolateral medium (Fig. 2B). Besides, ApoA-I, ApoA-
IV and ApoE de novo synthesis and secretion were substan-
tially enhanced. Of particular note was the induction of
ApoA-IV (400%, P6 0.01)
Lipoprotein production was assessed by following the
Table 1
Density of labeling for Ob-Rb in plasma membranes of con£uent and di¡erentiated Caco-2 cells
Caco-2 cell plasma membrane domains Anti-Ob-Rb/protein A^gold Protein A^gold
Apical membrane 0.06 þ 0.02 0.04 þ 0.01
Basolateral membrane 0.60 þ 0.10* 0.05 þ 0.01
Con£uent cells were ¢xed in situ with 1% glutaraldehyde and processed for embedding in Lowicryl at 320‡C. Thin sections were mounted on
Parlodion and carbon-coated nickel grids and processed for immunocytochemistry using the immunogold approach as described in Section 2.
For the quantitative evaluations, the plasma membrane pro¢les of 25 cells were recorded and printed to a ¢nal magni¢cation of U50 000. The
density of labeling present over the apical and basolateral membranes was evaluated by measuring the length of the membranes and the num-
ber of particles being aligned on such membranes. The results are expressed as the number of gold particles per length (Wm) of membrane. The
signi¢cance of the di¡erence in gold particle density between the basolateral and apical membranes was assessed by the Student t-test for un-
paired variants. *P6 0.01.
Table 2
E¡ect of hrLeptin on lipid synthesis by con£uent and di¡erentiated Caco-2 cells
Compartment
MG DG TG CE Total
Cells
C 61 658 þ 2213 1861 þ 99 186 793 þ 6340 2072 þ 171 253 193 þ 4267
T 62 922 þ 1484 1899 þ 67 194 297 þ 6597 2078 þ 120 261 938 þ 6953
% Control 102 þ 2.4 103 þ 5 103 þ 2.5 100 þ 3.2 103 þ 2.3
BL medium
C 936 þ 158 161 þ 24 10 645 þ 1330 164 þ 37 12 828 þ 1806
T 791 þ 102 141 þ 12 8045 þ 787* 127 þ 21 10 305 þ 1153
% Control 86 þ 8.1 90 þ 7.8 68 þ 6.8* 85 þ 7.9 82 þ 8.1
Cells were incubated with 200 nM hrLeptin for 8 h and lipids were analyzed as described in Section 2. Cells: intracellular content; BL me-
dium: basolateral medium content; C: control cells (n = 3); T: hrLeptin-treated cells (n = 6). Values are expressed as dpm/mg protein and as
means þ S.E.M. The signi¢cance of the di¡erence between the treated and control cells was assessed by Student’s t-test. *P6 0.01.
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[14C]oleic acid incorporation into the di¡erent density frac-
tions collected by ultracentrifugation: 0.95 (chylomicrons,
CM), 1.006 (very low-density lipoproteins, VLDL), 1.063
(low-density lipoproteins, LDL) and 1.21 g/ml (HDL). As
shown in Table 3, hrLeptin inhibited the secretion of CM
(89 þ 9%, P6 0.03) and of LDL (78 þ 18, P6 0.05). VLDL
and HDL remained una¡ected.
Of interest, when cells were incubated in presence of rhLep-
tin on the apical side, at the same concentration, no e¡ects
were observed on lipid esteri¢cation, apolipoprotein biogene-
sis or lipoprotein assembly (data not shown).
4. Discussion
Leptin, a cytokine-like peptide known to regulate food in-
take at the hypothalamus level [34], exerts its e¡ect through
the activation of the Janus kinase signal transducer and acti-
vator of transcription (STAT) signaling cascade [17,35].
Although Ob-Rb distribution was originally described in the
hypothalamus, its expression has subsequently been observed
in peripheral tissues as diverse as pancreatic islets [10], hem-
atopoietic stem cells and, more recently, in the stomach
[36,37]. Morton et al. [17] have shown, by RT-PCR, that
Ob-Rb was expressed in Caco-2 cells and that leptin, at con-
centrations similar to ours, caused the induction of immedi-
ate-early genes and activation of STAT3 and STAT5. They
did not, however, address its speci¢c function in intestinal
lipid metabolism.
In the present report, using established immunohistochem-
ical methods, we demonstrate that the leptin receptor (Ob-Rb)
is speci¢cally located on the basolateral membrane of fully
di¡erentiated Caco-2 cells (Fig. 1A and Table 1). We also
show that leptin inhibits the TG secretion (Table 2), the bio-
synthesis of ApoB-100 and ApoB-48 (Fig. 2A) as well as the
output of CM and LDL (Table 3). Although the concentra-
tion of leptin used is high, it may be that the concentration in
the receptor microenvironment is much less due either to a
low di¡usion of the peptide, its degradation with time or
adsorption on the plastic dish. However, the fact that the
e¡ects are observed only when the cytokine is present in the
basolateral medium militates in favor of a speci¢c action.
Furthermore, other studies performed in our laboratory re-
vealed that neither of the two other cytokines, transforming
growth factor-L or interferon-Q, a¡ected lipid metabolism (un-
published results).
Intestinal epithelial cells have the unique ability to elaborate
CMs, the major vehicle for the transport of dietary fat [38]. In
our investigation we document the in£uence of leptin on the
sequential events leading to the lipid output into the baso-
lateral compartment. We show that the administration of
the hormone, at the same concentration (200 nM) as that
used by Morton et al. [17], results in the decrease of TG
secretion without a¡ecting cell content, pointing to a lack of
hormonal e¡ect on the esteri¢cation process. The concomitant
diminution of CM and LDL delivery to the basolateral com-
partment indicates, on its part, that the lipoprotein assembly
process is the target of leptin action. This hypothesis is sup-
ported by the reduction of de novo-synthesized ApoB cell
content and presence in the basolateral medium. These data,
in turn, hint to ApoB being the limiting factor for CM deliv-
ery. Various reports have indeed demonstrated that the post-
translational translocation of the apolipoprotein across the
endoplasmic reticulum (ER) membrane is the rate-limiting
step in ApoB-containing lipoprotein formation [21,39].
The ER MTP/PDI heterodimer is crucial for the lipidation
and protection of ApoB from proteolysis as well as for the
enrichment of lipoprotein particles with TGs [40]. In view of
our data documenting a lack of e¡ect of hrLeptin on MTP
Fig. 2. E¡ect of hrLeptin on cellular content (A) and on basolateral
secretion (B) of de novo-synthesized apolipoproteins in fully di¡er-
entiated Caco-2 cells. Cells were incubated with 200 nM hrLeptin
for 3 h in presence of [35S]methionine and apolipoproteins were ana-
lyzed as described in Section 2. The results are the means þ S.E.M.
of six control and 6^10 leptin-treated cell incubations. Mean values
for the control experiments, expressed as dpm/mg proteins for each
apolipoprotein in the cell compartment were: ApoB-100: 16596;
ApoB-48: 9847; ApoA-I: 3843; ApoA-IV: 16078 and ApoE: 7209.
In the basolateral medium, the values were: ApoB-100: 19125;
ApoB-48: 9748; ApoA-I: 335; ApoA-IV: 437 and ApoE: 838. The
signi¢cance of the di¡erence between the treated and control cells
was assessed by Student’s t-test. *P6 0.01; **P6 0.05.
Table 3
E¡ect of hrLeptin on lipoprotein secretion in the basolateral medium by con£uent and di¡erentiated Caco-2 cells
CM VLDL LDL HDL
C 40 595 þ 6053 51 043 þ 14 398 9230 þ 1996 4952 þ 1031
T 33 236 þ 3590* 44 305 þ 7511 7064 þ 1086* 5440 þ 579
% Control 89 þ 3.9* 114.5 þ 5.7 78 þ 7.4* 99 þ 3.7
Cells were incubated with 200 nM hrLeptin for 20 h and lipoproteins were analyzed as described in Section 2. C: Control cells (n = 3); T:
hrLeptin-treated cells (n = 6). Values are expressed as dpm/mg protein and as means þ S.E.M. The signi¢cance of the di¡erence between the
treated and control cells was assessed by Student’s t-test. *P6 0.05.
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activity (data not shown), we suggest that this protein com-
plex is not implicated in the modulation of lipoprotein assem-
bly and exocytosis. These results are similar to those of Macri
et al. [41] who have recently shown, in HepG2 cells, that in-
hibition of MTP did not a¡ect the translocation of ApoB, but
facilitated its proteasome-mediated degradation, thereby im-
pacting on the assembly and secretion of ApoB particles.
Therefore, additional investigation is required to understand
the mechanisms by which leptin a¡ects lipoprotein metabo-
lism in Caco-2 cells.
Data on the direct e¡ect of leptin on enterocyte apolipo-
protein synthesis are scarce. Two reports address the e¡ect of
leptin on enterocyte apolipoprotein synthesis in in vivo mod-
els. In the ¢rst one [17], the authors have shown that an intra-
venous injection of leptin, 90 min after a fat load, caused a
two-fold reduction in ApoA-IV transcript levels in the jeju-
num of leptin-de¢cient mice (ob/ob). In the second, Doi et al.
[18] have recently reported a rapid (4 h) increase in ApoA-IV
immunoreactivity in rat jejunum and ileum following an intra-
duodenal lipid infusion. This stimulatory e¡ect was, however,
paradoxically attenuated by a simultaneous leptin infusion.
We show that, in Caco-2 cells fully di¡erentiated as entero-
cytes, ApoA-I, ApoA-IV and ApoE biosynthesis and secretion
were enhanced by leptin (Fig. 2). In terms of ApoA-IV, the
variance of our results with the aforementioned reports could
be due to the model used and the di¡erent experimental con-
ditions.
Our results indicate that leptin has a role in the absorptive
and metabolic functions of the enterocyte and could possibly
play an early role in limiting fat absorption. It could be con-
ceived that disruption of the leptin signaling pathway is ac-
quired in the obese state, leading to an impaired control of
intestinal lipid synthesis and export. This ‘resistance’ state
could then possibly lead to a more important and prolonged
post-prandial lipid load. Our results also support the hypoth-
esis that leptin can a¡ect energy balance through mechanisms
prior to and possibly independent of those described at the
hypothalamic level.
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